Use of proteomics to identify mechanisms of hepatocellular carcinoma with the CYP2D610 polymorphism and identification of ANGPTL6 as a new diagnostic and prognostic biomarker

• Published in: Journal of translational medicine 2021-08, Vol.19 (1), p.359-359, Article 359
• Main Authors: Hu, Guiming, Gao, Fei, Wang, Guanzhe, Fang, Yan, Guo, Yuanyuan, Zhou, Jun, Gu, Yuhan, Zhang, Cunzhen, Gao, Na, Wen, Qiang, Qiao, Hailing
• Format: Article
• Language: English
• Subjects: Alzheimer's disease; Angiopoietin; Angiopoietin-Like Protein 6; Angiopoietin-like Proteins - genetics; ANGPTL6; Biomarkers; Biomarkers, Tumor - genetics; Cancer therapies; Carcinoma, Hepatocellular - diagnosis; Carcinoma, Hepatocellular - genetics; Chromatography; CYP2D6; CYP2D6 protein; Cytochrome P-450; Cytochrome P-450 CYP2D6 - genetics; Cytochrome P450; Development and progression; Diagnosis; Enzymatic activity; Enzymes; Extracellular matrix; Gene polymorphism; Genetic aspects; Health aspects; Hepatocellular carcinoma; Hepatoma; Hospitals; Humans; Identification and classification; Laboratories; Lipid metabolism; Liver cancer; Liver Neoplasms - diagnosis; Liver Neoplasms - genetics; Mass spectrometry; Metabolism; Metabolites; Mutation; Peptides; Physiological aspects; Polymorphism; Polymorphisms; Prognosis; Protein expression; Proteins; Proteomes; Proteomics; Risk factors; Scientific imaging; Tumor markers; Tumor Microenvironment; α-Fetoprotein
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-021-03038-3

Although an association between the cytochrome P4502D6 (CYP2D6) *10 (100C>T) polymorphism and hepatocellular carcinoma (HCC) is known, the mechanism remains unclear. Here we aimed to explore mechanisms of CYP2D6*10 (100C>T) polymorphism conferring to HCC, and screen markers for HCC. Label-free global proteome profiling with 34 normal livers and peritumor tissue from 61 HCC patients was performed, and angiopoietin-like protein-6 (ANGPTL6) was evaluated in 2 liver samples validation cohorts and 2 blood specimens validation cohorts. We found a significantly decreased frequency of TT in HCC patients which reduced HCC susceptibility by 69.2% and was accompanied by lowered enzymatic activity for CYP2D6. Proteomic analysis revealed 1342 differentially expressed proteins (DEPs) that were associated with HCC and 88 DEPs were identified as 100 TT-related proteins, likely underlying the susceptibility to HCC. Twenty-two upregulated DEPs and 66 downregulated DEPs were mainly related to lipid metabolism and the extracellular matrix, respectively. High ANGPTL6 was associated with a higher risk to HCC and worse prognosis. ANGPTL6 was both an independent risk factor and an independent prognostic factor for HCC and exhibited strong potential for predicting HCC occurrence, with comparable AUC values and higher sensitivity compared with alpha-fetoprotein. The TT genotype-associated decreased risk of HCC appears to be related to lowered CYP2D6 activity and altered protein expression in the tumor microenvironment, and ANGPTL6 is a promising new diagnostic and prognostic biomarker for HCC. Our findings reveal new mechanistic insights for polymorphisms related to HCC risk and provide avenues for screening for HCC.